Biora Therapeutics Submits Updated IND Application for BT-600
October 30, 2023 16:05 ET
|
Biora Therapeutics, Inc.
Update includes supplemental information and provides additional time to complete regulatory review; company expects to remain on track with Ph1 timeline.
Inflammatory Bowel Disease Treatment Market to hit USD 39.19 Billion by 2030 | Fortune Business Insights
October 30, 2023 07:14 ET
|
Fortune Business Insights
Pune, India, Oct. 30, 2023 (GLOBE NEWSWIRE) -- The inflammatory bowel disease treatment market revenue is set to rise from USD 26.55 billion in 2023 to USD 39.19 billion by 2030 at a CAGR of 5.7%...
Inflammatory Bowel Disease Treatment Market Size to Surpass USD 37.00 Billion by 2029, exhibiting a CAGR of 5.7%
October 05, 2023 04:35 ET
|
Fortune Business Insights
Pune, India, Oct. 05, 2023 (GLOBE NEWSWIRE) -- The inflammatory bowel disease treatment market size was valued at USD 23.90 billion in 2021 and projected to grow USD 37.00 billion by 2029,...
Ulcerative Colitis Market Soars to $6.84 Billion in 2023, Registering a 7.7% CAGR - Unlocking Lucrative Investment Opportunities
September 20, 2023 04:43 ET
|
Research and Markets
Dublin, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The "Ulcerative Colitis Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global ulcerative colitis market is...
First Wave BioPharma to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Fecal Calprotectin Test Market revenue to hit USD 350 Million by 2035, says Research Nester
August 23, 2023 07:30 ET
|
Research Nester
New York, Aug. 23, 2023 (GLOBE NEWSWIRE) -- The global fecal calprotectin test market size is predicted to grow at a CAGR of over ~12% from 2023 to 2035. The market is projected to garner a revenue...
Fecal Calprotectin Test Market to Grow at 10.7% CAGR, Aiming for USD 355.8 Million by 2031 – TMR Report
May 24, 2023 06:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, May 24, 2023 (GLOBE NEWSWIRE) -- The global fecal calprotectin test market stood at US$ 126.9 million in 2022 and the global market is projected to reach US$...
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
April 25, 2023 07:00 ET
|
Morphic Therapeutic
-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in the Robarts Histopathology Index (RHI) Score- -MORF-057 achieves 25.7% clinical...
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
April 25, 2023 06:59 ET
|
Morphic Therapeutic
-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures with no...
Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023
April 24, 2023 16:01 ET
|
Morphic Therapeutic
WALTHAM, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...